SARS-CoV-2 vaccine-related adverse events in Zimbabwe: the need to strengthen pharmacovigilance in resource-limited settings

Grant Murewanhema, Tafadzwa Dzinamarira, Roda Madziva, Helena Herrera, Godfrey Musuka

    Research output: Contribution to journal › Letter › peer-review

    28 Downloads (Pure)
    Original languageEnglish
    JournalPharmacoepidemiology and Drug Safety
    DOIs
    Publication statusPublished - 9 Dec 2021

    Keywords

    • pharmacovigilance
    • Covid-19
    • limited resources

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    • SDG 3 - Good Health and Well-being

    Access to Document

    • 2021 - SARS‐CoV‐2 vaccine‐related adverse events in Zimbabwe

      This is the peer reviewed version of the following article: Murewanhema, G., Dzinamarira, T., Madziva, R., Herrera, H. and Musuka, G. (2022), SARS-CoV-2 vaccine-related adverse events in Zimbabwe: The need to strengthen pharmacovigilance in resource-limited settings. Pharmacoepidemiology and Drug Safety, which has been published in final form at 10.1002/pds.5393. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley’s version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited.

      Accepted author manuscript (Post-print), 298 KB

      Cite this